



29th August 2015

Aurobindo Pharma receives USFDA Approval for Raloxifene Hydrochloride Tablet

Aurobindo Pharma Limited is pleased to announce that the company has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Raloxifene Hydrochloride Tablets USP 60mg (ANDA 204310).

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Evista® Tablets, 60mg of Eli Lilly.

Raloxifene Hydrochloride Tablets are indicated for treatment and prevention of osteoporosis in postmenopausal women. The product has an estimated market size of US\$404 Million for the twelve months ending June 2015 according to IMS.

This is the 45th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. Aurobindo now has a total of 210 ANDA approvals (182 Final approvals including 9 from Aurolife Pharma LLC and 28 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited

Phone: 040-66725000 / 66725401

Email: ir@aurobindo.com

Website : www.aurobindo.com

Corporate Off: WaterMark Building, Level-1
Plot No.11, Survey No. 9
Kondapur, Hitech City, Hyderabad

Reg Off: Plot No. 2, Maitrivihar
Ameerpet, Hyderabad